Renoprotection with angiotensin type-1 receptor blockers in hypertension

Indian Heart Journal

Volumn 52, Issue 1, 2000, Pages 89-92

  Narain, V S ^a,b   Kochar, A ^a,b  

^a KING GEORGE'S MEDICAL UNIVERSITY   (India)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ENDOTHELIN; GROWTH FACTOR; NITRIC OXIDE; PLASMINOGEN ACTIVATOR INHIBITOR 1;

ADRENERGIC ACTIVITY; ESSENTIAL HYPERTENSION; HYPERTENSION; KIDNEY DISEASE; NOTE; PATHOPHYSIOLOGY; VASOCONSTRICTION;

ANGIOTENSIN I; ANGIOTENSIN II; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; HUMANS; HYPERTENSION; KIDNEY; RECEPTORS, ANGIOTENSIN;

EID: 0034080717     PISSN: 00194832     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Note

References (28)

1. Gavras I, Gavras H. Angiotensin II - Possible adverse effects on arteries, heart, brain and kidney: Experimental, clinical and epidemiological evidence. In : The renin angiotensin system. Robertson JIS, Nicholls MG, ed. London: Gower Medical Publishing, 1993; pp 40.1-40.11
2. Maschio G, Marcautoni C. Antiotensin converting enzyme inhibitors in non - diabetic renal disease. Curr Opin Nephrol Hypertens 1998; 7: 253-257.
3. Remuzzi G, Ruggenenti P, Benigni A. Understanding the nature of renal disease progression. Kidney Intern 1997; 51: 2-15
4. Blantz RC, Gabbai FB. Effect of angiotensin II on glomerular haemodynamics and ultrafiltration coefficient. Kidney Intern 1987; 31 (Suppl 20): 108-111
5. Lafayette RA, Mayer G, Park SK, Meyer TW. Angiotensin II receptor blockade limits glomerular injury in rats with reduced renal mass. J Clin Invest 1992; 90: 766-771
6. Remuzzi A, Puntorieri S, Batlaglia C, Dertani T, Remuzzi G. Angiotensin converting enzyme inhibition ameliorates glomerular filtration of macromolecules and water and lessens glomerular injury in the rat. J Clin Invest 1990; 85: 541-549
7. Giatras I, Lau J, Levey AS. Effect of angiotensin converting enzyme inhibitors on the progression of non diabetic renal disease: A meta analysis. Ann Intern Med 1997; 127: 337-345
8. Carr AA, Prisant LM. Losartan: First of a new class of angiotensin antagonists for the management of hypertension. J Clin Pharmacol 1996; 36: 3-12
9. Burnier M, Roch Ramel F, Brunner HR. Renal Effects of angiotensin II receptor blockade in normotensive subjects. Kidney Intern 1996; 49: 1778-1790
10. Wiemer G, Scholkens BA, Wagner A, Heitsch H, Linz W. The possible role of angiotensin II subtype AT-2 receptors in endothelial cells and isolated ischaemic rat hearts. J Hypertens 1993; 11 (Suppl 5): S234-S235
11. Mclanghlin K, Alan GJ. Angiotensin converting enzyme inhibitors and angiotensin receptor (AT-1) antagonists: Either or both for primary renal disease? Nephrol Dial Transplant 1999; 14: 25-28
12. Kohzuki M, Yasujima M, Liu PF, et al. Cardiovascular and renal protective effects of losartan in spontaneously hypertensive rats with diabetes mellitus. Clin Exp Pharm Physiol 1995; 22: S366-367
13. Zucchelli P, Zucchelli A, Borghi M, et al. Long term comparison between captopril and nifedipine in the progression of renal insufficiency. Kidney Intern 1992; 42: 455-458
14. Maschio G, Alberti D, Janin G, et al. Effect of angiotensin converting enzyme inhibitor benezepril on the progression of chronic renal insufficiency. N Engl J Med 1996; 334: 939-945
15. GISEN Group. A Randomized placebo controlled trial of effect of ramipril on the decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet 1997; 349: 1857-1863
16. The EUCLID Study Group. Randomized placebo controlled trial of lisinopril in normotensive patients with insulin dependent diabetes and normoalbuminuria or microalbuminuria. Lancet 1997; 349: 1787-1792
17. Ravid M, Lang R, Racrmani R, Liohner M. Long term reno- protective effect of angiotensin converting enzyme inhibition in non-insulin dependent diabetes mellitus: A 7-year follow up study. Arch Intern Med 1996; 156: 286-289
18. UK Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS-39. Br Med J 1998; 317: 713-720
19. Effect of angiotensin converting enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: The Captopril Prevention Project (CAPPP) randomized trial. Lancet 1999; 353: 611-616
20. Remuzzi A, Perico N, Amuchastegui CS, et al. Short-and long- term effect of angiotensin II receptor blockade in rats with experimental diabetes. J Am Soc Nephrol 1993; 4: 40-49
21. Remuzzi A, Malanchini B, Battaglia C, Bertani T, Remuzzi G. Comparison of the effects of angiotensin-converting enzyme inhibition and angiotensin II receptor blockade on the evolution of spontaneous glomerular injury in male MWF/Ztm rats. Exp Nephrol 1996; 4: 19-25
22. Gansevoort R, de Zeeuw D, Shahinfar S, Redfield A, de Jong PE. Effects of the angiotensin II antagonist losartan in hypertensive patients with renal disease. J Hypertens 1994; 12 (Suppl 2): S37-S42
23. Gansevoort RT, de Zeeuw D, de Jong PE. Is the antiproteinuric effect of ACE inhibition mediated by interference in the renin- angiotensin system? Kidney Intern 1994; 45: 861-867
24. Chan JCN, Critchley JAJH, Tomlinson B, Chan TYK, Cockram CS. Antihypertensive and anti-albuminuric effects of losartan, potassium and felodipine in Chinese elderly hypertensive patients with or without non-insulin dependent diabetes mellitus. Am J Nephrol 1997; 17: 72-80
25. Nielsen S, Dollerup J, Nielsen B, Jensen HAE, Mogensen CE. Losartan reduces albuminuria in patients with essential hypertension: An enalapril controlled 3 months study. Nephrol Dial Transplant 1997; 12 (Suppl 2): 19-23
26. Toto R, Shultz P, Raij L, et al. Efficacy and tolerability of losartan in hypertensive patients with renal impairment. Hypertension 1998; 31: 684-691
27. Holdaas H, Hartmann A, Berg KJ, Lund K, Fauchald P. Renal effects of losartan and amlodipine in hypertensive patients with non diabetic nephropathy. Nephrol Dial Transplant 1998; 13: 3096-3102
28. Rodby RA. Antihypertensive treatment in nephropathy of type II diabetes: Role of the pharmacological blockade of renin-angiotensin system. Nephrol Dial Transplant 1997; 12: 1095-1096